Engineered Etoposide-Prednisolone Co-nanocrystals for Synergistic Antitumor Efficacy Enhancement
Open Access
- 1 January 2026
- journal article
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (20) , 5838-5849
Abstract
The present work consists in developing new organic crystalline nanomedicines, namely co-nanocrystals (co-NCs), that associate a chemotherapy with an anti-inflammatory active pharmaceutical ingredient (API) in their nanocrystalline forms. These mixed...Keywords
Funding Information
- Fondation Maladies Rares (317758 IEA-2021)
- Fondation Maladies Rares (CNRS-22-01)
- Fondation Maladies Rares (061001)
This publication has 48 references indexed in Scilit:
- Hybrid Nanocrystalline Theranostic Agents Designed for Magnetic Resonance Imaging, Photothermal, and Photodynamic Therapies Against CancerNano Select, 2026
- Step‐By‐Step Standardization of the Bottom‐Up Semi‐Automated Nanocrystallization of Pharmaceuticals: A Quality By Design and Design of Experiments Joint ApproachSmall, 2024
- Reinforcement learning strategies in cancer chemotherapy treatments: A reviewComputer Methods and Programs in Biomedicine, 2022
- Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first‐line intensified treatment of pediatric patients with high‐risk acute lymphoblastic leukemia in CoALL08‐09 trialPediatric Blood & Cancer, 2022
- Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight CancerAdvanced Materials, 2021
- The in vivo fate of nanocrystalsDrug Discovery Today, 2017
- Recent development of targeted approaches for the treatment of breast cancerBreast Cancer, 2016
- Novel Top‐Down Technologies: Effective Production of Ultra‐Fine Drug Nanocrystals2013
- Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicinBiomaterials, 2010
- Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinicCritical Reviews in Oncology/Hematology, 2007